USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Secretech, Inc.
Address:
1025 18th Street South
Birmingham, AL 35205
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $497,263.00 10
SBIR Phase II $1,228,393.00 3

Award List:

HUMAN PARAINFLUENZA TYPE 2 VIRUS GLYCOPROTEIN GENES

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,108.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

EVALUATION OF A MICROENCAPSULATED PARAINFLUENZA VACCINE

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Miroslav Novak
Abstract:
The long-term objective of this project is to develop a commercial trivalent glycoprotein subunit vaccine for parainfluenza viruses. because of the high cost of preparing these glycoproteins, a means for achieving an enhanced immune response is an important objective and is the focus of this… More

VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Yumiko Matsuoka
Abstract:
N/a

HUMAN PARAINFLUENZA TYPE 2 VIRUS GLYCOPROTEIN GENES

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$499,576.00
Agency:
HHS
Principal Investigator:
Abstract:
It is planned to construct a cdna library of human parainfluenza type 2 virus mrna's into a plasmid vector. the library will be screened by colony hybridization. the genes encoding envelope glycoproteins will be identified using specific probes in southern blot analysis, translationof mrna's, and… More

NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Moldoveanu, Zina , Principal Investigator
Abstract:
N/a

VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$290,133.00
Agency:
HHS
Principal Investigator:
Yumiko Matsuoka
Abstract:
The long-term objective of this study is the development of an effective delivery system for a live human rotavirus vaccine. to avoid the inactivation of virus by gastric acid, different buffers are being given before vaccination in current vaccine trials. this project focuses on the improvement of… More

NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$438,684.00
Agency:
HHS
Principal Investigator:
Moldoveanu, Zina , Principal Investigator
Abstract:
The purpose of the phase i study is to explore a novel approach for influenza virus vaccination by using microencapsulated antigens administered by the oral or intranasal route in order to induce a protective mucosal immune response. mice will be immunized with purified influenza virus type a h3n2… More

Novel Adjuvant to Enhance Immunity Against PIV3

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Prasanna Kumar
Abstract:
We will apply a novel adjuvant to the production of an effective, safe vaccine against PIV3. The proposed adjuvant is a proprietary formulation of microcrystalline cellulose, starch, and sugar. We will use a hamster model to test the ability of the novel adjuvant to enhance the immune response to… More

CTB as an Oral Adjuvant for Parainfluenza Vaccine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$48,156.00
Agency:
HHS
Principal Investigator:
Kumar Prasanna
Abstract:
The long term objective is to develop a commercial trivalent glycoprotein subunit vaccine for parainfluenza viruses. Because of the high cost of preparing these glycoproteins, a means for achieving an enhanced immune response is an important objective, and it is the immediate focus. The… More

Microencapsulated Respiratory Syncytial Virus Vaccine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Miroslav Novak
Abstract:
The long term objective is to develop a commercial subunit vaccine for human respiratory syncytial virus (RSV). Because of the high cost of preparing these glycoproteins, a means for achieving an enhanced immune response is an important objective, and it is the focus. Biocompatible and biodegradable… More

Mucosal Immunity Against Non-infectious SIV Particles

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,999.00
Agency:
HHS
Principal Investigator:
Prasanna Kumar
Abstract:
The long term objective is to induce a protective mucosal immune response to prevent HIV-1 infection. We will immunize orally with recombinant defective SIV-like particles entrapped in microcapsules of lactige-glyco- lide copolymer in order to stimulate a mucosal immune response in mice. The… More

Mucosal Vaccine for Sexually Transmitted Chlamydia

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Miroslav Novak
Abstract:
The long term objective is to develop a commercial vaccine for the prophylactic treatment of sexually transmitted Chlamydia trachomatis. Parenteral or oral delivery of free antigen does not protect against genital infection and, therefore, development of an antigen delivery method that induces a… More

Microencapsulated Measles Virus Vaccine

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Zina Moldoveanu
Abstract:
The long term objective is to develop a commercial subunit vaccine against MV infection. Because of the high cost of preparing the surface antigens, a means for achieving an enhanced immune response is an important objective and is the focus. Biocompatible and biodegradable microspheres consisting… More